-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $73

Benzinga·10/19/2026 10:28:02
语音播报
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $65 to $73.